NeuroOne (NMTC) Chief Business Officer David Wambeke Buys Shares

What Happened

• David J. Wambeke, Chief Business Officer of NeuroOne Medical Technologies (NMTC), completed an open-market purchase and received a stock award. On 2026-08-27 he purchased 33,333 shares at an average price of $2.01 per share for a total of $66,999. On 2026-08-28 he was granted 35,000 shares as a reported derivative award (price $0.00).

Key Details

• Transaction dates and prices:
  • 2026-08-27 — Open-market purchase (Code P): 33,333 shares @ $2.01 each; total $66,999.
  • 2026-08-28 — Grant/award (Code A, derivative): 35,000 shares @ $0.00; total $0.
• Vesting (Footnote F2): 25% vests on August 28, 2027; remaining 75% vests in 12 equal quarterly installments thereafter.
• Price note (Footnote F1): The reported purchase price is a weighted average of multiple transactions; the filing notes prices ranged from $2.00 to $2.017 per share and that full per-transaction detail will be provided upon SEC request.
• Shares owned after the transaction: Not disclosed in the provided filing.
• Filing timeliness: No late filing flag indicated in the provided data.

Context

• This filing shows both a purchase (direct open-market buy) and a compensated award subject to vesting. Purchases by insiders can be interpreted by investors as a stronger signal than grants, but filings are factual records and do not state the insider’s motivation.
• The award is a derivative/compensatory grant with a multi-stage vesting schedule — not an immediate free transfer of unrestricted shares.